Logo image of ROIV

ROIVANT SCIENCES LTD (ROIV) Stock Overview

USA - NASDAQ:ROIV - BMG762791017 - Common Stock

16.04 USD
-0.08 (-0.5%)
Last: 10/10/2025, 8:55:55 PM
16.05 USD
+0.01 (+0.06%)
After Hours: 10/10/2025, 8:55:55 PM

ROIV Key Statistics, Chart & Performance

Key Statistics
52 Week High16.79
52 Week Low8.73
Market Cap10.95B
Shares682.88M
Float425.86M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.7
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO12-03 2020-12-03
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ROIV short term performance overview.The bars show the price performance of ROIV in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

ROIV long term performance overview.The bars show the price performance of ROIV in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200

The current stock price of ROIV is 16.04 USD. In the past month the price increased by 13.92%. In the past year, price increased by 34.79%.

ROIVANT SCIENCES LTD / ROIV Daily stock chart

ROIV Latest News, Press Relases and Analysis

ROIV Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.77 407.19B
AMGN AMGEN INC 13.3 156.19B
GILD GILEAD SCIENCES INC 15.14 145.40B
VRTX VERTEX PHARMACEUTICALS INC 24.07 104.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.36B
REGN REGENERON PHARMACEUTICALS 12.37 59.85B
ARGX ARGENX SE - ADR 85.97 48.77B
ONC BEONE MEDICINES LTD-ADR 5.17 35.16B
INSM INSMED INC N/A 34.31B
BNTX BIONTECH SE-ADR N/A 24.54B
NTRA NATERA INC N/A 23.23B
BIIB BIOGEN INC 9.15 21.49B

About ROIV

Company Profile

ROIV logo image Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Company Info

ROIVANT SCIENCES LTD

7Th Floor, 50 Broadway

London GB

Employees: 750

ROIV Company Website

ROIV Investor Relations

Phone: 4412955950

ROIVANT SCIENCES LTD / ROIV FAQ

What is the stock price of ROIVANT SCIENCES LTD today?

The current stock price of ROIV is 16.04 USD. The price decreased by -0.5% in the last trading session.


What is the ticker symbol for ROIVANT SCIENCES LTD stock?

The exchange symbol of ROIVANT SCIENCES LTD is ROIV and it is listed on the Nasdaq exchange.


On which exchange is ROIV stock listed?

ROIV stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ROIVANT SCIENCES LTD stock?

18 analysts have analysed ROIV and the average price target is 20.04 USD. This implies a price increase of 24.96% is expected in the next year compared to the current price of 16.04. Check the ROIVANT SCIENCES LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ROIVANT SCIENCES LTD worth?

ROIVANT SCIENCES LTD (ROIV) has a market capitalization of 10.95B USD. This makes ROIV a Large Cap stock.


How many employees does ROIVANT SCIENCES LTD have?

ROIVANT SCIENCES LTD (ROIV) currently has 750 employees.


What are the support and resistance levels for ROIVANT SCIENCES LTD (ROIV) stock?

ROIVANT SCIENCES LTD (ROIV) has a support level at 16.03 and a resistance level at 16.17. Check the full technical report for a detailed analysis of ROIV support and resistance levels.


Is ROIVANT SCIENCES LTD (ROIV) expected to grow?

The Revenue of ROIVANT SCIENCES LTD (ROIV) is expected to decline by -75.92% in the next year. Check the estimates tab for more information on the ROIV EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ROIVANT SCIENCES LTD (ROIV) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ROIVANT SCIENCES LTD (ROIV) stock pay dividends?

ROIV does not pay a dividend.


What is the Price/Earnings (PE) ratio of ROIVANT SCIENCES LTD (ROIV)?

ROIVANT SCIENCES LTD (ROIV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.7).


What is the Short Interest ratio of ROIVANT SCIENCES LTD (ROIV) stock?

The outstanding short interest for ROIVANT SCIENCES LTD (ROIV) is 8.5% of its float. Check the ownership tab for more information on the ROIV short interest.


ROIV Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to ROIV. When comparing the yearly performance of all stocks, ROIV is one of the better performing stocks in the market, outperforming 89.44% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ROIV Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to ROIV. No worries on liquidiy or solvency for ROIV as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ROIV Financial Highlights

Over the last trailing twelve months ROIV reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS increased by 9.09% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -9.75%
ROE -11.29%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-375%
Sales Q2Q%-96.06%
EPS 1Y (TTM)9.09%
Revenue 1Y (TTM)-79.1%

ROIV Forecast & Estimates

18 analysts have analysed ROIV and the average price target is 20.04 USD. This implies a price increase of 24.96% is expected in the next year compared to the current price of 16.04.

For the next year, analysts expect an EPS growth of -477.03% and a revenue growth -75.92% for ROIV


Analysts
Analysts85.56
Price Target20.04 (24.94%)
EPS Next Y-477.03%
Revenue Next Year-75.92%

ROIV Ownership

Ownership
Inst Owners65.29%
Ins Owners3.93%
Short Float %8.5%
Short Ratio5.49